文献速递胸部肿瘤放疗放疗物理与技术

免疫细胞有效辐射剂量预测局部晚期非小细胞肺癌的淋巴细胞减少及更差肿瘤控制

The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC.
PubMed 文献 · Radiother Oncol · 2023-11-24

该回顾性研究纳入786例接受放化疗(部分联合巩固免疫治疗)的局部晚期非小细胞肺癌患者,中位免疫细胞有效剂量(EDIC)为4.7 Gy。EDIC与更差的无进展生存和总生存相关,并可预测4级淋巴细胞减少;光子治疗较质子治疗与更高EDIC相关。

要点

  • EDIC中位值为4.7 Gy,EDIC<4.7 Gy者中位PFS为15.3个月、OS为34.2个月,均优于≥4.7 Gy者。
  • 多变量模型中EDIC与PFS(HR 1.08)和OS(HR 1.10)独立相关。
  • EDIC可预测4级淋巴细胞减少(OR 1.16),并与2级及以上肺炎及非计划住院增加相关。

核心结论

  • EDIC与更差的疾病结局、治疗相关毒性及严重淋巴细胞减少的发生相关。
  • 质子治疗与更低的EDIC相关。
  • 作者认为进一步研究限制免疫系统辐射剂量似乎是合理的。

研究设计与样本

  • 回顾性分析十年期间所有接受放化疗(联合或不联合巩固免疫治疗)的局部晚期非小细胞肺癌患者,共786例,其中228例接受巩固免疫治疗。
  • 使用Cox比例风险模型和Kaplan-Meier法分析EDIC与PFS、OS的关联,采用逻辑回归分析淋巴细胞减少和较高EDIC的预测因素。
  • EDIC分别作为连续变量和分类变量进行分析,淋巴细胞减少按CTCAE v5.0分级。

主要发现

  • 中位EDIC为4.7 Gy。
  • EDIC<4.7 Gy组中位PFS为15.3个月,≥4.7 Gy组为9.0个月(p<0.001);EDIC<4.7 Gy组中位OS为34.2个月,≥4.7 Gy组为22.4个月(p<0.001)。
  • 多变量模型中,EDIC与更差PFS相关(HR 1.08,95%CI 1.01-1.14,p=0.014),与更差OS相关(HR 1.10,95%CI 1.04-1.18,p=0.002)。
  • EDIC可预测4级淋巴细胞减少(OR 1.16,95%CI 1.02-1.33,p=0.026)。
  • EDIC≥4.7 Gy与2级及以上肺炎增加相关(6个月发生率26% vs 20%,p=0.04),与非计划住院增加相关(90天发生率40% vs 30%,p=0.002)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论提出进一步研究限制免疫系统辐射剂量似乎是合理的。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To explore the association of the effective dose to immune cells (EDIC) with disease control, lymphopenia, and toxicity in patients with non-small cell lung cancer (NSCLC) and identify methods to reduce EDIC. METHODS: We abstracted data from all patients with locally advanced NSCLC treated with chemoradiation with or without consolidative immunotherapy over a ten-year period. Associations between EDIC and progression-free survival (PFS) and overall survival (OS) were modeled with Cox proportional hazards and Kaplan-Meier method. Logistic regression was used to model predictors of lymphopenia and higher EDIC. Analyses were performed with EDIC as a continuous and categorical variable. Lymphopenia was graded per CTCAE v5.0. RESULTS: Overall, 786 patients were included (228 of which received consolidative immunotherapy); median EDIC was 4.7 Gy. Patients with EDIC < 4.7 Gy had a longer median PFS (15.3 vs. 9.0 months; p < 0.001) and OS (34.2 vs. 22.4 months; p < 0.001). On multivariable modeling, EDIC correlated with inferior PFS (HR 1.08, 95 % CI 1.01-1.14, p = 0.014) and OS (HR 1.10, 95 % CI 1.04-1.18, p = 0.002). EDIC was predictive of grade 4 lymphopenia (OR 1.16, 95 % CI 1.02-1.33, p = 0.026). EDIC ≥ 4.7 Gy was associated with increased grade 2 + pneumonitis (6-month incidence: 26 % vs 20 %, p = 0.04) and unplanned hospitalizations (90-day incidence: 40 % vs 30 %, p = 0.002). Compared to protons, photon therapy was associated with EDIC ≥ 4.7 Gy (OR 5.26, 95 % CI 3.71-7.69, p < 0.001) in multivariable modeling. CONCLUSIONS: EDIC is associated with inferior disease outcomes, treatment-related toxicity, and the development of severe lymphopenia. Proton therapy is associated with lower EDIC. Further investigations to limit radiation dose to the immune system appear warranted.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Friedes C, Iocolano M, Lee SH, et al. The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC. Radiother Oncol. 2023. PMID: 38008414. doi:10.1016/j.radonc.2023.110030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。